UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2021

Commission File Number: 001-34541

GLOBAL CORD BLOOD CORPORATION

(Translation of registrant's name into English)

48th Floor, Bank of China Tower

1 Garden Road Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

EXPLANATORY NOTE

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or Global Cord Blood Corporation's (the "Company") future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company's expectations are as of the date of this Report on Form 6-K, and the Company does not intend to update any of the forward-looking statements after the date of this Report on Form 6-K to conform these statements to actual results, unless required by law.

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: the effects of the current 2019 novel coronavirus ("COVID-19") outbreak, including the inability of the Company's salesforce to return to work due to current lockdowns implemented in various cities in the PRC and the imposition by some hospitals in the PRC of restrictions on entrance to solely to hospital staff and patients; levels of consumer confidence in the healthcare services sector generally in the PRC as a result of the outbreak; the length of the COVID-19 outbreak and severity of such outbreak across the globe; the pace of recovery following the COVID-19 outbreak; continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of legislative developments affecting U.S. listed issuers whose independent registered public accounting firms are based in the PRC and not subject to U.S. Public Company Accounting Oversight Board inspections, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions, and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

2

Results of Operations and Financial Condition

Following this cover page are the unaudited condensed consolidated financial results for the three months and nine months ended December 31, 2020 of the Company.

GLOBAL CORD BLOOD CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and December 31, 2020

	March 31, 2020	December 31, 2020	December 31, 2020		
	RMB	RMB (in thousands except share data)	US\$		
ASSETS		in thousands except share data)			
Current assets					
Cash and cash equivalents	5,473,373	5,867,754	899,274		
Accounts receivable, less allowance for doubtful accounts (March 31, 2020:	, ,		,		
RMB111,869; December 31, 2020: RMB124,205 (US\$19,035))	104,251	128,962	19,765		
Inventories	43,758		8,750		
Prepaid expenses and other receivables	44,785		8,771		
Total current assets	5,666,167		936,560		
Property, plant and equipment, net	522,679		77,996		
Operating lease right-of-use assets	4,548		854		
Non-current deposits	347,360		52,568		
Non-current accounts receivable, less allowance for doubtful accounts (March 31,	,	,	,		
2020: RMB71,421; December 31, 2020: RMB70,125 (US\$10,747))	160,031	202,658	31,059		
Inventories	85,109		13,813		
Intangible assets, net	92,823		13,695		
Investment in equity securities at fair value	101,306		18,690		
Other equity investment	189,129		28,985		
Deferred tax assets	50,701		8,244		
Total assets	7,219,853		1,182,464		
LIABILITIES					
Current liabilities					
Accounts payable	19,992	9,743	1,493		
Accrued expenses and other payables	113,989	- , -	19,653		
Operating lease liabilities	1,717		478		
Deferred revenue	402,751		64,881		
Income tax payable	32,329		4,144		
Total current liabilities	570,778		90,649		
Non-current deferred revenue	2,289,762		362,827		
Non-current operating lease liabilities	1,782		30		
Other non-current liabilities	450,900		72,642		
Deferred tax liabilities	18,140		2,604		
Total liabilities	3,331,362		528,752		
	5,551,55	3,130,101	5=0,75=		
EQUITY					
Shareholders' equity of Global Cord Blood Corporation					
Ordinary shares					
- US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075					
shares issued and outstanding as of March 31 and December 31, 2020, respectively	83	83	13		
Additional paid-in capital	2,101,582		322,082		
Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares,	, - ,	, - ,	- ,		
respectively)	(2,815) (2,815)	(431)		
Accumulated other comprehensive losses	(94,663		(15,876)		
Retained earnings	1,877,940		346,122		
Total equity attributable to Global Cord Blood Corporation	3,882,127		651,910		
Non-controlling interests	6,364		1,802		
Total equity	3,888,491		653,712		
Total liabilities and equity	7,219,853		1,182,464		
······································	.,=10,000		-,-0=,107		

4

GLOBAL CORD BLOOD CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Nine Months Ended December 31, 2019 and 2020

203 203 203 203 203 203 RMB RMB RMB RMB RMB RMB VIS Revenues 334,733 290,798 44,567 921,572 857,318 131 Cost of revenues (51,606) (44,479) (6,677) (145,670) (133,309) (20 Gross profit 284,522 37,689 775,992 724,279 111 Operating expenses (21,457) (21,453) (17,504) (18,233) (27,671) (21,453) (17,17) (17,504) (18,232) (56 Coperating expenses (130,254) (121,963) (18,692) (366,208) (366,208) (30,27,652) (50 Operating income 152,673 123,957 110,993 30,107 4 133 Change in fair value of equity scurities 8,047 6,003 920 10,983 30,107 4 Dividend income 4,515 2,152 33 5,675 59,408 <		Three months ended December 31,		Nine months ended December 31,			
(In thousands except per share data) Revenues 334,733 290,798 44,567 921,572 857,318 131 Cost of revenues (51,606) (44,478) (6,6478) (145,670) (133,039) (20 Gross profit 283,127 245,920 37,689 775,902 724,279 111 Operating expenses Research and development (6,404) (8,985) (1,377) (17,504) (18,283) (22 Sales and marketing (75,536) (68,994) (10,574) (147,251) (131,191) (20 General and administrative (47,914) (43,984) (6,741) (147,251) (131,191) (20 Otle operating income 152,873 123,957 18,997 409,694 396,627 60 Other income, net 1 11.1164 183 11.1164 183 11.1164 183 11.1164 183 11.1164 183 11.1164 183 11.1164 11.117 11.1164 11.118 11.1164 11.1164 <td< th=""><th></th><th>2019</th><th>202</th><th>20</th><th>2019</th><th>2020</th><th></th></td<>		2019	202	20	2019	2020	
Cost of evenues (51.606) (44.878) (6.878) (145.670) (133.039) (20 Gross profit 283,127 245,920 37,689 (775,902) 724,279 111 Operating expenses <th></th> <th>RMB</th> <th>RMB</th> <th></th> <th></th> <th>RMB</th> <th>US\$</th>		RMB	RMB			RMB	US\$
Cost of evenues (51.606) (44.878) (6.878) (145.670) (133.039) (20 Gross profit 283,127 245,920 37,689 (775,902) 724,279 111 Operating expenses <td>Revenues</td> <td>334,733</td> <td>290,798</td> <td>44.567</td> <td>921.572</td> <td>857.318</td> <td>131,389</td>	Revenues	334,733	290,798	44.567	921.572	857.318	131,389
Gross profit Operating expenses 283,127 245,920 37,689 775,902 724,279 111 Operating expenses (6,404) (8,985) (1,377) (17,504) (18,283) (2 Sales and marketing (75,936) (68,994) (10,574) (147,251) (118,283) (2 General and administrative (47,914) (43,984) (6,741) (147,251) (131,191) (20 Total operating expenses (130,254) (121,963) (18,692) (366,208) (327,652) (50 Opter income, net 1 1.02 19,072 22,767 3 Change in fair value of equity securities 8,047 6,003 920 10,983 30,107 4 Dividend income - - - 5,077 1,281 0 1,383 15,420 2,343 35,675 59,408 9 Income targe prise forme tax 171,811 139,377 21,360 445,369 456,035 69 Income tacw expense (25,644) (21,220) <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td>,</td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td>(20,389)</td>		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	,	· · · · · · · · · · · · · · · · · · ·	(20,389)
Operating expenses Control Research and development (6,404) (8,985) (1.377) (17,504) (18,283) (2 Sales and marketing (75,936) (68,994) (10,574) (201,453) (178,178) (27 General and administrative (47,914) (43,984) (6,741) (147,251) (131,191) (20 Total operating expenses (130,254) (121,963) (18,692) (366,208) (327,652) (50 Operating income (5,350) (110,21,963) (18,997) 409,694 396,627 60 Other income, net - 507 1,281 Uvided income 4 4 - 143,937 133,9377 13,938 145,420 <					· · · ·		111,000
Research and development (6,404) (8,985) (1,377) (17,504) (18,283) (2 Sales and marketing (75,936) (68,994) (10,574) (201,453) (178,178) (27 General and diministrative (47,914) (43,984) (67,41) (147,251) (131,191) (20 Total operating expenses (130,254) (121,963) (18,692) (366,208) (327,652) (60 Other income, net - 507 1.1 (164) 183 - Others income of equity securities 8,047 6,003 920 10,983 30,107 4 Dividend income - - - - 507 1,2136 0 35,675 59,408 9 Income before income tax 171,811 139,377 2,1360 445,369	-	200,127	2-10,020	57,005	775,502	/,_/0	111,000
Sales and marketing (75,936) (68,994) (10,574) (201,453) (178,178) (27 General and administrative (47,914) (43,984) (6,741) (147,251) (131,191) (20 Otal operating expenses (100,254) (121,963) (18,692) (366,208) (362,7652) (56 Other income, net 1 123,957 18,997 409,694 396,627 60 Interest income 6,350 7,190 1,102 19,072 22,767 3 Foreign currency exchange gains/(losses) 26 75 11 (164) 183 183 123,937 12,330 32,77 5,070 12,281 100 100 123,838 35,675 59,408 9 100 12,838 15,420 2,363 35,675 59,408 9 100 <td></td> <td>(6 404)</td> <td>(8 985)</td> <td>(1.377)</td> <td>(17504)</td> <td>(18 283)</td> <td>(2,802)</td>		(6 404)	(8 985)	(1.377)	(17504)	(18 283)	(2,802)
General and administrative (47,914) (43,984) (6,741) (147,251) (131,191) (20 Total operating expenses (130,254) (121,963) (18,992) (366,208) (327,652) (50 Operating income 152,873 123,957 18,997 409,694 396,627 60 Other income, net 6,350 7,190 1,102 19,072 22,767 3 Foreign currency exchange gains/(losses) 26 75 11 (164) 183 Change in fair value of equity securities 8,047 6,003 920 10,983 30,107 4 Dividend income - - - 507 1,281 0 Others 4,515 2,152 330 5,277 5,070 0 Income kar expense (25,644) (21,220) (3,252) (67,207) (70,131) (10 Net income attributable to non- controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Glo	-						(27,307)
Total operating expenses (130,254) (121,963) (18,692) (366,208) (327,652) (50 Operating income 152,873 123,957 18,997 409,694 396,627 60 Other income, net							(20,106)
Operating income 152,873 123,957 18,997 409,694 396,627 60 Other income, net - <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>(50,215)</td>							(50,215)
Other income, net 6,350 7,190 1,102 19,072 22,767 3 Interest income 6,350 7,190 1,102 19,072 22,767 3 Change in fair value of equity securities 8,047 6,003 920 10,983 30,107 4 Dividend income - - - - 507 1,281 Others 4,515 2,152 330 5,277 5,070 5 Total other income, net 18,938 15,420 2,363 35,675 59,408 9 Income tax expense (25,644) (21,220) (3,252) (67,207) (70,131) (10 Net income attributable to non- controlling interests (1,154) (1,587) (243) (4,452) (5,391) 0 Net income attributable to Global Cord Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: - Basic 1.19 0.96 0.15 3.07 3.13 0	1 0 1						60,785
Interest income 6,350 7,190 1,102 19,072 22,767 3 Foreign currency exchange gains/(losses) 26 75 11 (164) 183 Change in fair value of equity securities 8,047 6,003 920 10,983 30,107 4 Dividend income - - - 507 1,281 1 Others 4,515 2,152 330 5,277 5,070 1 Total other income, net 18,938 15,420 2,363 35,675 59,408 9 Income before income tax 171,811 139,377 21,360 445,369 456,035 69 Income tax expense (25,644) (21,220) (3,252) (67,207) (70,131) (10 Net income attributable to onon- controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Odola Cord 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: - Basic 1.19		152,075	120,007	10,557	405,054	550,027	00,705
Foreign currency exchange gains/(losses) 26 75 11 (164) 183 Change in fair value of equity securities 8,047 6,003 920 10,983 30,107 4 Dividend income - - - 507 1,281 Others 4,515 2,152 330 5,277 5,070 Total other income, net 18,938 15,420 2,363 35,675 59,408 9 Income tax expense (25,644) (21,220) (3,252) (67,207) (70,131) (10 Net income 146,167 118,157 18,108 378,162 385,904 59 Net income attributable to non- controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Global Cord Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: - <		6 350	7 190	1 102	19 072	22 767	3,489
Change in fair value of equity securities 8,047 6,003 920 10,983 30,107 4 Dividend income - - - 507 1,281 Others 4,515 2,152 330 5,277 5,070 Total other income, net 18,938 15,420 2,363 35,675 59,408 9 Income before income tax 171,811 139,377 21,360 445,369 456,035 69 Income tax expense (25,644) (21,220) (3,252) (67,207) (70,131) (10 Net income 146,167 118,157 18,108 378,162 385,904 59 Net income attributable to Global Cord Blood Corporation's shareholders (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Global Cord Blood Corporation's shareholders 116,570 17,865 373,710 380,513 58 Earnings per share: - - - - - - - Other comprehensive losses, net of nil income taxes - - - - -		- ,	,	, -	-) -		28
Dividend income			-		()		4,614
Others 4,515 2,152 330 5,277 5,070 Total other income, net 18,938 15,420 2,363 35,675 59,408 9 Income before income tax 171,811 139,377 21,360 445,369 456,035 69 Income tax expense (25,644) (21,220) (3,252) (67,207) (70,131) (10 Net income attributable to non- controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Global Cord Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Basic 1.19 0.96 0.15 3.07 3.13 Other comprehensive losses, net of nil income taxes (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income 115,214 113,868 17,451 370,362 376,974 57 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452)	8	0,047	0,005	520			196
Total other income, net 18,938 15,420 2,363 35,675 59,408 9 Income before income tax 171,811 139,377 21,360 445,369 456,035 693 Income tax expense (25,644) (21,220) (3,252) (67,207) (70,131) (10 Net income 146,167 118,157 18,108 378,162 385,904 59 Net income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Global Cord 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: 1.19 0.96 0.15 3.07 3.13 - Other comprehensive losses, net of nil income taxes 1.19 0.96 0.15 3.07 3.13 - Other comprehensive income 115,214 113,868 17,451 370,362 376,974 57 Comprehensive income (1,154) (1,587) (243) (4,452) (5,391) - <		4 515	2 152	330		,	777
Income before income tax 171,811 139,377 21,360 445,369 456,035 69 Income tax expense (25,644) (21,220) (3,252) (67,207) (70,131) (10 Net income 146,167 118,157 18,108 378,162 385,904 59 Net income attributable to non- controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Global Cord Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: - Basic 1.19 0.96 0.15 3.07 3.13 - Other comprehensive losses, net of nil income taxes 1.19 0.96 0.15 3.07 3.13 - Comprehensive income 115,214 113,868 17,451 370,362 376,974 57 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) -		· · · · · · · · · · · · · · · · · · ·	,		-)		9,104
Income tax expense (25,644) (21,220) (3,252) (67,207) (70,131) (10 Net income 146,167 118,157 18,108 378,162 385,904 59 Net income attributable to onon- controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Global Cord Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: Attributable to ordinary shares 1.19 0.96 0.15 3.07 3.13 3.13 Diluted 1.19 0.96 0.15 3.07 3.13 3.13 Other comprehensive losses, net of nil income taxes (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income 115,214 113,868 17,451 370,362 376,974 57 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Cord Blood Corporation's (1,154) (1,587) (243) (4,452) (5,391)			,				69.889
Net income 146,167 118,157 18,108 378,162 385,904 59 Net income attributable to non- controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Global Cord Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: - Basic 1.19 0.96 0.15 3.07 3.13 - Diluted 1.19 0.96 0.15 3.07 3.13 - Diluted 1.19 0.96 0.15 3.07 3.13 - Other comprehensive losses, net of nil income taxes (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income 115,214 113,868 17,451 370,362 376,974 57 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391)							(10,748)
Net income attributable to non- controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Global Cord Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: Attributable to ordinary shares 1.19 0.96 0.15 3.07 3.13 - Basic 1.19 0.96 0.15 3.07 3.13 - - Diluted 1.19 0.96 0.15 3.07 3.13 - Other comprehensive losses, net of nil income taxes - - - - - - Foreign currency translation adjustments (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Corporation's (1,154) (1,587) (243) (4,452) (5,391)	•			· ·			<u>(10,748)</u> 59,141
controlling interests (1,154) (1,587) (243) (4,452) (5,391) Net income attributable to Global Cord Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: Attributable to ordinary shares 119 0.96 0.15 3.07 3.13 0 Diluted 1.19 0.96 0.15 3.07 3.13 0 Other comprehensive losses, net of nil income taxes (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income 115,214 113,868 17,451 370,362 376,974 57 Comprehensive income attributable to Global Cord Blood Corporation's (1,154) (1,587) (243) (4,452) (5,391)		140,107	110,157	10,100	370,102	505,904	59,141
Net income attributable to Global Cord Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Earnings per share: Attributable to ordinary shares - Basic 1.19 0.96 0.15 3.07 3.13		(1 154)	(1 5 9 7)	(747)	(4.452)	(E 201)	(826)
Blood Corporation's shareholders 145,013 116,570 17,865 373,710 380,513 58 Earnings per share:		(1,134)	(1,367)	(243)	(4,432)	(3,391)	(820)
Earnings per share: Attributable to ordinary shares - Basic 1.19 0.96 0.15 3.07 3.13 - Diluted 1.19 0.96 0.15 3.07 3.13 Other comprehensive losses, net of nil income taxes - Foreign currency translation adjustments (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income 115,214 113,868 17,451 370,362 376,974 57 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391)		1/15 013	116 570	17 865	373 710	380 513	58,315
Attributable to ordinary shares - Basic 1.19 0.96 0.15 3.07 3.13 - Diluted 1.19 0.96 0.15 3.07 3.13 Other comprehensive losses, net of nil income taxes - - - - Foreign currency translation adjustments (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income 115,214 113,868 17,451 370,362 376,974 57 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Corporation's	blood Corporation's shareholders	145,015	110,570	17,005	575,710	500,515	50,515
- Basic 1.19 0.96 0.15 3.07 3.13 - Diluted 1.19 0.96 0.15 3.07 3.13 Other comprehensive losses, net of nil income taxes	Earnings per share:						
- Diluted 1.19 0.96 0.15 3.07 3.13 Other comprehensive losses, net of nil income taxes - Foreign currency translation adjustments (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Cord Blood Corporation's	Attributable to ordinary shares						
Initial0.1300.1130.1310.131Other comprehensive losses, net of nil income taxes - Foreign currency translation adjustments(30,953)(4,289)(657)(7,800)(8,930)(1)Comprehensive income115,214113,86817,451370,362376,97457Comprehensive income attributable to non-controlling interests(1,154)(1,587)(243)(4,452)(5,391)Comprehensive income attributable to Global Cord Blood Corporation's(1,154)(1,587)(243)(4,452)(5,391)	- Basic	1.19	0.96	0.15	3.07	3.13	0.48
income taxes - Foreign currency translation adjustments (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Cord Blood Corporation's	- Diluted	1.19	0.96	0.15	3.07	3.13	0.48
income taxes - Foreign currency translation adjustments (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Cord Blood Corporation's							
- Foreign currency translation adjustments (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Cord Blood Corporation's							
adjustments (30,953) (4,289) (657) (7,800) (8,930) (1 Comprehensive income 115,214 113,868 17,451 370,362 376,974 57 Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Corporation's (1,154) (1,587) (243) (4,452) (5,391)							
Comprehensive income115,214113,86817,451370,362376,97457Comprehensive income attributable to non-controlling interests(1,154)(1,587)(243)(4,452)(5,391)Comprehensive income attributable to Global Cord Blood Corporation'sGlobal Cord Blood Corporation'sGlobal Cord Blood Corporation'sGlobal Cord Blood Corporation's	5	(30.953)	(4.289)	(657)	(7.800)	(8,930)	(1,369)
Comprehensive income attributable to non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Cord Blood Corporation's	5						57,772
non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Cord Blood Corporation's	F		110,000		570,502		57,772
non-controlling interests (1,154) (1,587) (243) (4,452) (5,391) Comprehensive income attributable to Global Cord Blood Corporation's	Comprehensive income attributable to						
Comprehensive income attributable to Global Cord Blood Corporation's	-	(1,154)	(1,587)	(243)	(4,452)	(5,391)	(826)
Global Cord Blood Corporation's			,				
		114,060	112,281	17,208	365,910	371,583	56,946
5			5				

Other Events

On February 24, 2021, the Company issued a press release announcing unaudited condensed consolidated financial results for the three months and nine months ended December 31, 2020. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.		Description	
99.1	Press Release dated February 24, 2021		
		6	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLOBAL CORD BLOOD CORPORATION

By:	/s/ Albert Chen
Name:	Albert Chen
Title:	Chief Financial Officer

Dated: February 24, 2021

回際臍帶血庫企業集團 Global Cord Blood Corporation

Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021

Added 17,802 New Subscribers in 3Q21 Conference Call to be Held on February 25, 2021, at 8:00 a.m. ET

HONG KONG, China, February 24, 2021 — Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal 2021, ended December 31, 2020.

Third Quarter Fiscal 2021 Highlights

- Revenues decreased by 13.1% year-over-year ("YoY") to RMB290.8 million (\$44.6 million).
- New subscribers and accumulated subscriber base were 17,802 and 882,982¹, respectively.
- Gross profit decreased by 13.1% YoY to RMB245.9 million (\$37.7 million). Gross margin remained at 84.6%, same as the prior year period.
- Operating income decreased by 18.9% YoY to RMB124.0 million (\$19.0 million). Operating margin decreased to 42.6% from 45.7% in the prior year period.
- Operating income before depreciation and amortization ("non-GAAP operating income"²) decreased by 17.4% YoY to RMB136.3 million (\$20.9 million).
- Net income attributable to the Company's shareholders decreased by 19.6% to RMB116.6 million (\$17.9 million).
- Net cash provided by operating activities was RMB145.0 million (\$22.2 million).

Nine Month Fiscal 2021 Highlights

- Revenues decreased by 7.0% YoY to RMB857.3 million (\$131.4 million).
- New subscribers and accumulated subscriber base were 52,678 and 882,982¹, respectively.
- Gross profit decreased by 6.7% YoY to RMB724.3 million (\$111.0 million).
- · Operating income decreased by 3.2% YoY to RMB396.6 million (\$60.8 million).
- Non-GAAP operating income² decreased by 3.0% YoY to RMB433.5 million (\$66.4 million).
- Net income attributable to the Company's shareholders increased by 1.8% to RMB380.5 million (\$58.3 million), mainly due to the increase in fair value of equity securities ("mark-to-market gains").
- Net cash provided by operating activities was RMB419.6 million (\$64.3 million).

"Despite the ongoing challenges due to COVID-19, lower newborn numbers, and cautious consumer sentiment, we managed to recruit 17,802 new subscribers in the third quarter, keeping us on track to meet our annual target," said Ms. Ting Zheng, Chief Executive Officer and Chairperson of GCBC. "Although the National Health Commission announced a new policy that no cord blood banking license applications would be accepted in 2021, new developments on industry regulations remain largely uncertain. As such, we must continue to communicate with regulatory bodies and remain vigilant regarding other changes that may arise within the industry. We intend to leverage our advantages as the industry leader to increase penetration in existing markets and seize available opportunities to expand our business and services."

Summary — Third Quarter and Nine Months Ended December 31, 2019 and 2020

	Three Mon	ths Ended December 3	1,	Nine Mont	hs Ended December 3	1,
_	2019	2020		2019	2020	
(in thousands)	RMB	RMB	US\$	RMB	RMB	US\$
Revenues	334,733	290,798	44,567	921,572	857,318	131,389
Gross Profit	283,127	245,920	37,689	775,902	724,279	111,000
Operating Income ³	152,873	123,957	18,997	409,694	396,627	60,785
Change in Fair Value of Equity Securities	8,047	6,003	920	10,983	30,107	4,614
Net Income Attributable to the						
Company's Shareholders	145,013	116,570	17,865	373,710	380,513	58,315
Earnings per Ordinary Share (RMB/US\$)						
– Basic	1.19	0.96	0.15	3.07	3.13	0.48
– Diluted	1.19	0.96	0.15	3.07	3.13	0.48
Revenues Breakdown (%)						
Processing Fees and Other Services	65.3%	56.8%		63.6%	57.3%	
Storage Fees	34.7%	43.2%		36.4%	42.7%	
New Subscribers (persons)	23,387	17,802		65,753	52,678	
Total Accumulated Subscribers (persons)	815,000	882,9821		815,000	882,9821	

Summary — Selected Cash Flow Statement Items

	Three Months Ended December 31,			Nine Months Ended December 31,		
	2019	2020		2019	2020	
(in thousands)	RMB	RMB	US\$	RMB	RMB	US\$
Net cash provided by operating activities	156,031	144,988	22,222	534,042	419,631	64,313
Net cash used in investing activities	(139,806)	(5,996)	(919)	(145,035)	(17,316)	(2,654)
Net cash used in financing activities		_	—	(4,039)	(6,074)	(931)

Third Quarter Fiscal 2021 Financial Results

REVENUES. Revenues decreased by 13.1% YoY to RMB290.8 million (\$44.6 million) in the third quarter of fiscal 2021, mainly due to a drop in new subscribers which resulted in lower revenues from processing fees and other services.

During the reporting quarter, the 2019 novel coronavirus ("COVID-19") pandemic continued to affect the Company's hospital channels and business operations. In addition, newborn numbers in the Company's operating markets remained on a downward trend. These factors led to a 23.9% YoY decrease in new subscribers to 17,802. Revenues generated from processing fees and other services in the reporting quarter decreased by 24.4% YoY to RMB165.2 million (\$25.3 million), representing 56.8% of total revenues compared to 65.3% in the prior year period.

As of December 31, 2020, the accumulated subscriber base had expanded to 882,982¹. Revenues generated from storage fees increased by 8.0% YoY to RMB125.6 million (\$19.3 million) in the reporting quarter.

GROSS PROFIT. Gross profit for the third quarter decreased by 13.1% YoY to RMB245.9 million (\$37.7 million). As general cost reductions resulting from lower volumes were offset by higher costs associated with raw material and labor, gross margin remained at 84.6%, same as in the prior year period.

OPERATING INCOME. Operating income for the reporting quarter decreased by 18.9% YoY to RMB124.0 million (\$19.0 million). Operating margin was 42.6% compared to 45.7% in the prior year period. Depreciation and amortization expenses for the third quarter were RMB12.3 million (\$1.9 million), compared to RMB12.1 million in the prior year period. Non-GAAP operating income² decreased by 17.4% YoY to RMB136.3 million (\$20.9 million) in the reporting quarter.

Research and Development Expenses. As the Company continued to support science and technology advancement related to the utilization of cord blood stem cells through old and new collaborations, research and development expenses in the third quarter increased to RMB9.0 million (\$1.4 million) from RMB6.4 million in the prior year period.

Sales and Marketing Expenses. During the reporting quarter, the Company enhanced its marketing and promotional efforts, resulting in higher advertising and promotional expenses. The impact was, however, partially offset by lower staff renumeration on the back of a smaller salesforce. As a result, sales and marketing expenses decreased by 9.1% YoY to RMB69.0 million (\$10.6 million).

General and Administrative Expenses. General and administrative expenses decreased by 8.2% YoY to RMB44.0 million (\$6.7 million) due to reduced staff costs and professional fees while partially offset by higher provisions. General and administrative expenses as a percentage of revenues was 15.1% compared to 14.3% in the prior year period.

OTHER INCOME.

Change in fair value of equity securities. In the reporting period, the Company recognized a mark-to-market gain of RMB6.0 million (\$0.9 million), compared to a mark-to-market gain of RMB8.0 million in the prior year period. The changes were mainly attributable to the Company's investments in equity securities.

NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. Income before income tax for the third quarter decreased by 18.9% YoY to RMB139.4 million (\$21.4 million). Income tax expense for the third quarter was RMB21.2 million (\$3.3 million). Net income attributable to the Company's shareholders for the reporting quarter decreased by 19.6% YoY to RMB116.6 million (\$17.9 million). Net margin for the reporting quarter was 40.1%.

EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the third quarter of fiscal 2021 was RMB0.96 (\$0.15).

Nine Month Fiscal 2021 Financial Results

Total revenues for the first nine months of fiscal 2021 decreased by 7.0% YoY to RMB857.3 million (\$131.4 million). The decrease was mainly due to the decline in new subscribers. Revenues from processing fees and other services decreased by 16.3% YoY to RMB491.1 million (\$75.3 million), whereas revenues from storage fees increased by 9.2% YoY to RMB366.2 million (\$56.1 million). Gross profit decreased by 6.7% YoY to RMB724.3 million (\$111.0 million). Operating income decreased by 3.2% YoY to RMB396.6 million (\$60.8 million). Non-GAAP operating income² decreased by 3.0% YoY to RMB433.5 million (\$66.4 million). Net income attributable to the Company's shareholders improved by 1.8% to RMB380.5 million (\$58.3 million). Basic and diluted earnings per ordinary share increased to RMB3.13 (\$0.48). Net cash provided by operating activities in the first nine months of fiscal 2021 was RMB419.6 million).

Corporate Developments

 On June 4, 2019, the Board of Directors of the Company (the "Board") received a non-binding proposal letter (the "Cordlife Proposal") from Cordlife Group Limited ("Cordlife"), a company listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX"), pursuant to which Cordlife proposed to combine its business with that of the Company, by way of a statutory merger. According to the Cordlife Proposal, Cordlife would issue approximately 2,497.9 million ordinary shares at an issue price of SGD0.5 per ordinary share in exchange for all of the Company's outstanding ordinary shares at \$7.50 per ordinary share. Upon completion of the proposed transaction, the Company's ordinary shares would be delisted from the New York Stock Exchange, and Cordlife ordinary shares would continue to trade on the SGX. On June 5, 2019, the Board formed a special committee of independent directors (the "Special Committee"), unaffiliated with Cordlife, to evaluate such proposal.

On November 11, 2019, the Company appointed Mr. Jack Chow as an independent non-executive director ("INED") of the Board. Mr. Chow has extensive professional experience and a broad network in the finance and investment industry. He replaced Mr. Mark Chen as a member of the Audit Committee and Ms. Jennifer Weng as a member of the Special Committee. Mr. Chow also joined the Board's Compensation Committee and Nominating and Corporate Governance Committee.

On February 6, 2020, the Company appointed Mr. Jacky Cheng as an INED of the Board. Mr. Cheng has extensive professional experience and knowledge of legal and compliance as well as Chinese laws. He joined as a member of both the Board's Compensation Committee and the Company's Special Committee. Currently, the Special Committee is composed of four members, including Mr. Mark Chen, Dr. Ken Lu, Mr. Jack Chow, and Mr. Jacky Cheng.

On February 11, 2021, the Company announced that the Board and the board of Cordlife have mutually agreed to discontinue any further discussions regarding the Cordlife Proposal.

Conference Call

The Company will host a conference call at 8:00 a.m. ET on Thursday, February 25, 2021, to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through the Company's IR website at http://ir.globalcordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for seven days at the same URL above. Listeners can also access the call by dialing 1-646-722-4977 or 1-855-824-5644 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 28530146#.

² See exhibit 3 to this press release for a reconciliation of non-GAAP operating income to exclude the non-cash items related to the depreciation and amortization expenses to the comparable financial measure prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").

³ The reported operating income for the three months ended December 31, 2019 and 2020 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB12.1 million and RMB12.3 million (\$1.9 million), respectively. The reported operating income for the nine months ended December 31, 2019 and 2020 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB36.9 million (\$5.7 million), respectively.

¹ During the three months and nine months ended December 31, 2020, 17,802 and 52,678 new subscribers were recruited, respectively. During the three months and nine months ended December 31, 2020, the Company determined that the recoverability of 2,000 and 2,790 private cord blood units was remote; therefore, the Company terminated their subscription services according to the subscription contracts. Out of these prior private cord blood units, 1,600 and 2,390 prior private cord blood units were being treated as if they were donated cord blood units and will be part of the Company's non-current inventories. Hence, the net accumulated subscriber base was 882,982 as of December 31, 2020.

Use of Non-GAAP Financial Measures

GAAP results for the three months and nine months ended December 31, 2020, include non-cash items related to depreciation and amortization expenses. To supplement the Company's unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company's management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company's historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.

About Global Cord Blood Corporation

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at: http://www.globalcordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: the effects of the current COVID-19 outbreak, including the inability of the Company's salesforce to return to work due to current lockdowns implemented in various cities in the PRC and the imposition by some hospitals in the PRC of restrictions on entrance to solely to hospital staff and patients; levels of consumer confidence in the healthcare services sector generally in the PRC as a result of the outbreak; the length of the COVID-19 outbreak and severity of such outbreak across the globe; the pace of recovery following the COVID-19 outbreak; continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of legislative developments in the U.S. affecting listed issuers whose independent registered public accounting firms are based in China and not subject to U.S. Public Company Accounting Oversight Board inspections, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions, and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the period ended December 31, 2020 were made at the noon buying rate of RMB6.5250 to \$1.00 on December 31, 2020 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. Global Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

For more information, please contact:

Global Cord Blood Corporation Investor Relations Department Tel: (+852) 3605-8180 Email: ir@globalcordbloodcorp.com

ICR, Inc. William Zima Tel: (+86) 10-6583-7511 U.S. Tel: (646) 405-5185 Email: William.zima@icrinc.com

GLOBAL CORD BLOOD CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and December 31, 2020

KNB KNB UIX ASSETS (in theusands except share data) Cash and cash equivalents 5,473,373 5,867,754 899,274 Accounts receivable, less allowance for doubtrhil accounts (March 31, 2020: 104,251 128,962 19,765 Inventories 44,785 57,231 8,771 506,6167 6111,042 998,550 Prepaid expenses and other receivables 44,785 57,231 8,771 104 0076 508,204 77,996 Operating lease right-focus assets 5,454 5,573 854 Non-current deposits 347,300 343,006 52,568 Non-current deposits 2020: RMB71,421; December 31, 2020: RMB70,125 (US\$10,747) 160,031 202,653 31,059 Inventories 101,306 121,951 18,699 01,32 13,813 Intangulte assets, net 101,304 121,951 18,699 11,824 Defered tax asset 50,701 53,794 8,244 11,899 122,233 19,653 Operating lease fiabilities 19,992 9,743 1,493		March 31, December 31, 2020 2020		,
ASSETS Cash and cash equivalents 5,473,373 5,867,754 899,274 Accounts receivable, less allowance for doubful accounts (March 31, 2020: 128,962 19,765 Inventories 43,773 5,867,754 899,274 Accounts receivable, less allowance for doubful accounts (March 31, 2020: 8,771 1741 128,962 19,765 Inventories 44,785 57,231 8,771 1741 1042 996,560 Oppertylip lata and equipment, net 522,679 506,924 77,996 0peratry, Jpat and equipment, net 522,679 343,006 52,568 31,059 Non-current doposits 347,360 343,006 52,568 31,059 10,202,658 31,059 Inventories 55,109 90,132 13,813 11,036 121,951, 18,690 Orber equity investment 19,219 189,219 189,829 189,129 28,883 Inventories 50,711 53,734 8,244 16,300 113,939 122,233 14,433 Inventories 50,711 53,734 8,244 16,30		RMB	RMB	US\$
Current assets 5,473,373 5,867,754 899,274 Cash and cash equivalents 5,473,373 5,867,754 899,274 Accounts receivable, less allowance for doubtful accounts (March 31, 2020: 128,962 19,765 RMB11,869; December 31, 2020; RMB124,205 (US\$19,035)) 104,251 128,962 8,750 Prepaid expenses and other receivables 44,785 57.231 8,771 Total current assets 5666,167 6,111,044 936,560 Property, plant and equipment, net 522,679 508,924 77,996 Non-current deposits 347,360 343,006 52,568 Non-current deposits 347,360 90,132 13,035 Intragible assets, net 101,306 121,951 18,059 Intragible assets, net 101,306 121,951 18,059 Intragible assets 50,701 53,794 8,244 Total assets 7,219,853 7,715,566 1,182,46 Current assets 13,989 1,242,33 1,963 Intragible assets, net 1,717 3,116 478	ASSETS	(1	in thousands except share data)	
Cash and cash equivalents 5,473,373 5,867,754 899,274 Accounts receivable, less allowance for doubtful accounts (March 31, 2020: 104,251 128,962 19,765 Inventories 43,778 57,005 8,750 Prepaid expenses and other receivables 44,785 57,231 8,771 Total current assets 5,866,167 6,111,042 936,560 Operating lease right-of-use assets 4,548 5,573 854 Non-current decounts receivable, less allowance for doubtful accounts (March 31, 2020: RMB71,421; December 31, 2020: RMB70,125 (US\$10,747)) 160,031 202,658 31,059 Non-current decounts receivable, less allowance for doubtful accounts (March 31, 2020: RMB71,421; December 31, 2020: RMB70,125 (US\$10,747)) 160,031 202,658 31,059 Non-current decounts receivable, less allowance for doubtful accounts (March 31, 2020: RMB71,421; December 31, 2020: RMB71,421; December 31, 2020: RMB71,421; December 31, 2020: RMB71,421; December 31, 2020: RMB70,125 (US\$10,747)) 160,031 202,658 31,049 Non-current doubtines 92,823 89,357 13,805 121,951 18,809 Other equity investment 189,129 128,931 14,833 124,244 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Accounts receivable, less allowance for doubful accounts (March 31, 2020: RMB111,869; December 31, 2020: RMB124,205 (US\$19,035)) 104,251 128,962 19,765 Inventories 43,758 57,095 8,750 Prepaid expenses and other receivables 44,768 57,231 8,771 Total current assets 55666,167 6,111,042 9396,560 Property, plans and equipment, net 522,679 508,924 77,996 Operating less argith-of-use assets 44,548 5,573 854 Non-current accounts receivable, less allowance for doubful accounts (March 31, 2020: RMB71,421; December 31, 2020: RMB70,125 (US\$10,747)) 160,031 202,658 31,059 Inventories 8,109 90,132 13,813 Intragible assets, net 92,823 99,357 13,695 Investment in equity securities at fair value 101,306 121,951 18,690 Other equity investment 1818,129 189,129 28,935 Deferred tax assets 5,07,01 53,794 8,244 Total assets 750,701 53,794 8,244 Total assets 750,701 53,794 8,244 Total assets 750,701 53,794 8,244 Total assets 113,989 128,223 19,653 Operand [ease liabilities 11,12,12,12,12,12,12,12,12,12,12,12,12,1		5.473.373	5.867.754	899.274
RMB111,669; December 31, 2020; RMB124,205 (USS19,035)) 104,251 128,662 19,765 Inventories 43,758 57,095 8,750 Prepaid expenses and other receivables 44,785 57,231 0,771 Total current assets 5,666,167 6,111,042 936,560 Operating lease right-of-use assets 4,548 5,573 854 Non-current deposits 347,360 343,006 52,568 Non-current deposits 347,360 343,006 52,568 Non-current deposits 347,360 90,132 13,813 Inventories 85,109 90,132 13,813 Inventories 98,5109 90,132 13,813 Investment in equity securities at fair value 101,306 121,951 18,690 Other equity investment 189,129 189,323 1,862 Deferred tax assets 7,715,566 1,182,464 1,182,464 LIABILITIES 7,219,433 7,715,566 1,182,464 Deferred revenue 10,929 9,743 1,493 Accruan		_,,	-,,	
Inventories 43,758 57,095 8,750 Prepaid expenses and other recivables 44,785 57,231 8,771 Total current assets 5,666,167 6,111,042 936,560 Property, plant and equipment, net 522,679 508,924 77,996 Operating lease right-of-use assets 44,448 5,573 854 Non-current deposits 347,360 343,006 52,568 Non-current deposits 347,360 90,132 13,813 Investories 85,109 90,132 13,813 Investories 92,823 89,357 13,869 Other equity investment 190,129 189,129 28,985 Investories 50,701 53,794 8,244 Total assets 50,701 53,794 8,244 Total assets 1,171 3,116 478 Current liabilities 1,171 3,116 478 Accounts payable 19,992 9,743 1,493 Deferred rax assets 50,707 591,480 90,643		104.251	128.962	19,765
Prepaid expenses and other receivables 44,785 57.231 8,771 Total current assets 5.666,167 6.111,042 936,560 Property, Junt and equipment, net 522,679 508,924 77,99 Operating lease right-of-use assets 4.448 5.573 854 Non-current deposits 347,300 343,006 522,687 Vacurent accounts receivable, less allowance for doubtful accounts (March 31, 2020; RMB71,421; December 31, 2020; RMB70,125 (US\$10,747)) 160,031 202,658 31,059 Investment in equity securities at fair value 101,306 121,951 18,909 Other equity investment 199,129 189,129 28,985 Deferred tax assets 7,219,853 7,715,566 1,182,464 LIABILITIES T 7,219,853 7,715,566 1,182,464 Deferred tax assets 13,989 128,233 19,653 Operating lease liabilities 1,177 3,116 478 Deferred revenue 402,751 423,350 64,841 Income ax payable 19,992 2,367,446 362,927			,	
Total current assets 5.666,167 6.111,042 936,560 Property, plant and equipment, net 522,679 508,924 77,996 Operating lease right-of-use assets 4,548 5,573 854 Non-current deposits 347,360 343,006 52,568 Non-current cocunts receivable, less allowance for doubiful accounts (March 31, 2020: RMB71,421; December 31, 2020: RMB70,125 (US\$10,747)) 160,031 202,658 31,059 Intrangible assets, net 92,823 89,357 13,695 Investment in equity securities at fair value 101,306 121,951 18,690 Other equity investment 189,129 189,8129 28,985 Deferred tax assets 70,701 53,734 8,244 Total assets 7,715,566 1,182,464 LIABILITIES Current liabilities 1,177 3,116 478 Deferred revenue 402,751 423,350 64,881 Income tax payable 1,277 423,350 64,881 Non-current dabilities 1,777 51,400 90,649 Non-current operating lease liabil				
Property, plant and equipment, net 522,679 508,924 77.996 Operating lease right-of-use assets 4,548 5,573 854 Non-current deposits 347,360 342,006 52,568 Non-current accounts receivable, less allowance for doubtful accounts (March 31,				
Operating lease right-of-use assets 4,548 5,573 854 Non-current deposits 347,360 343,006 52,568 Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2020; RMB71,421; December 31, 2020; RMB70,125 (US\$10,747)) 160,031 202,658 31,059 Inventories 85,109 90,132 13,813 Intargible assets, net 92,823 89,357 13,695 Investoment in equity securities at fair value 101,306 121,951 18,690 Other equity investment 189,129 189,129 28,985 Deferred tax assets 50,701 53,794 8,244 Total assets 7,219,853 7,715,566 1,182,464 LIABILITIES Current liabilities 1,717 3,116 478 Accounts payable 19,992 9,743 1,493 Accurd expenses and other payables 1,717 3,116 478 Deferred revenue 402,751 423,350 64,881 10,613 90,649 Non-current liabilities 1,717 3,146 478,229 72,038 <td< td=""><td></td><td></td><td></td><td>-</td></td<>				-
Non-current accounts receivable, less allowance for doubthl accounts (March 31,				
Non-current accounts receivable, less allowance for doubful accounts (March 31, 2020: RMB71,421; December 31, 2020: RMB70,125 (US\$10,747)) 160,031 202,683 31,059 Inventories 85,109 90,132 13,813 Intangible assets, net 92,823 89,357 13,695 Investment in equity securities at fair value 101,306 121,951 18,690 Other equity investment 189,129 189,129 28,2855 Deferred tax assets 50,701 53,794 8,244 Total assets 7,219,853 7,715,566 11,82,464 Current liabilities - - - - Accounds payable 19,992 9,743 1,493 - Accounds payable 19,992 9,743 1,493 - Deferred revenue 402,751 423,350 64,881 Income tax payable 13,989 128,244 - Total current liabilities 7,715,566 41,844 Non-current liabilities 1,782 19,503 3,64,881 Income tax payable 1,782 2,36				
2020: RMB71,421; December 31, 2020: RMB70,125 (US\$10,747)) 160.031 202,658 31,059 Inventories 85,109 90,132 13,813 Intangible assets, net 92,823 89,357 13,695 Investment in equity securities at fair value 101,306 121,951 18,690 Other equity investment 189,129 189,129 28,985 Deferred tax assets 50,701 53,794 8,244 Total assets 7,219,853 7,715,566 1,182,464 LIABILITIES 4,244 Current liabilities 1 1,992 9,743 1,493 Accrued expreases and other payables 113,989 128,233 19,653 Operating lease liabilities 1,717 3,116 478 Deferred revenue 402,751 423,350 64,881 Income tax payable 32,329 27,038 4,144 Total current liabilities 1,772 195 30 Non-current liabilities 1,782 195 30 Other ono-current liabil		547,500	545,000	52,500
Inventories 85,109 90,132 13,813 Intangible assets, net 92,823 89,357 13,605 Investment in equity securities at fair value 101,306 121,951 18,690 Other equity investment 189,129 189,129 28,985 Deferred tax assets 50,701 53,794 8,244 Total assets 7,715,566 1,182,464 Current liabilities 7,719,853 7,715,566 1,182,464 Deferred tax assets 19,992 9,743 1,493 Accounts payable 19,992 9,743 1,493 Operating lease liabilities 1,717 3,116 478 Deferred revenue 402,751 423,350 64,881 Income tax payable 32,329 2,038 4,144 Deferred revenue 2,289,762 2,367,446 362,827 Non-current liabilities 1,782 195 30 Other non-current liabilities 450,900 473,990 2,264,752 Deferred rax liabilities 1,81,40 16,990		160 031	202 658	31.059
Intangible assets, net 92,823 89,357 13,695 Investment in equity securities at fair value 101,306 121,951 18,690 Other equity investment 189,129 188,129 28,985 Deferred tax assets 50,701 53,794 8,244 Total assets 7,219,853 7,715,566 1,182,464 LIABILITIES 4,043 Accrued expenses and other payables 113,989 128,233 19,653 Operating lease liabilities 1,717 3,116 478 Deferred revenue 402,751 423,350 64,881 Income tax payable 32,329 27,038 4,144 Total current liabilities 1,782 195 30 Non-current operating lease liabilities 1,782 195 30 Other onor-current liabilities 1,782 195 30 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 3,31,362 3,450,101 52,875 Shareholders' equity of Glob			·	
Investment in equity securities at fair value 101,306 121,951 18,690 Other equity investment 189,129 189,129 28,985 Deferred tax assets 50,701 53,794 8,244 Total assets 7,219,853 7,715,566 1,182,464 LIABILITIES 20,001 53,794 8,244 Accounts payable 19,992 9,743 1,493 4,245 Accounts payable 19,992 9,743 1,493 4,2623 19,553 0,071 3,116 478 4,721 3,116 478 4,721 3,116 478 4,721 3,116 478 4,721 1,717 3,116 478 4,824 402,751 423,350 64,881 10000000 1,717 3,116 478 9,703 4,144 104 104,990 2,604 30,229 7,038 4,144 104 105,990 2,604 30,229 7,238 4,144 104,5990 2,604 104,5990 2,604 104,5990 2,604 104,				
Other equity investment 189,129 189,129 189,129 28,985 Deferred tax assets 50,701 53,794 8,244 Total assets 7,219,853 7,715,566 1,182,464 LIABILITIES 4 </td <td></td> <td></td> <td></td> <td></td>				
Deferred tax assets 50,701 53,794 8,244 Total assets 7,219,853 7,715,566 1,182,464 LIABILITIES				
Total assets 7,219,853 7,715,566 1,182,464 LIABILITIES Current liabilities 19,992 9,743 1,493 Accounts payable 19,992 9,743 1,493 Accrued expenses and other payables 113,899 128,233 19,653 Operating lease liabilities 1,717 3,116 478 Deferred revenue 402,751 422,350 64,881 Income tax payable 32,329 27,038 4,144 Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current liabilities 1,782 195 30 Other non-current liabilities 1,782 195 30 Other non-current liabilities 3,331,362 3,450,101 528,752 EQUITY Shareholders' equity of Global Corporation 19,510,75 share sissued and outstanding as of March 31 and December 31, 2020, respectively 83 13 Additional paid-in capital 2,202, respectively 83 83 13	1 5			
LIABILITIES Current liabilities Accounts payable 19,992 9,743 1,493 Accounts payable 113,989 128,233 19,653 Operating lease liabilities 1,717 3,116 478 Deferred revenue 402,751 423,350 64,881 Income tax payable 32,229 27,038 4,144 Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 450,900 473,990 2,642 Deferred tax liabilities 18,140 16,990 2,604 Total liabilities 33,31,362 3,450,101 528,752 EQUITY Shareholders' equity of Global Cord Blood Corporation 70 51,687,974 and 121,551,075 51,848 3 13 Additional paid-in capital 2,100,582 2,101,582 3,20,82 322,082 Treasury stock, at cost (March 31 and December 31, 20				
Current liabilities Accounts payable 19,992 9,743 1,493 Accrued expenses and other payables 113,989 128,233 19,653 Operating lease liabilities 1,717 3,116 478 Deferred revenue 402,751 423,350 64,881 Income tax payable 32,329 27,038 4,144 Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 18,140 16,990 2,604 Total liabilities 3,331,362 3,450,101 528,752 Deferred tax liabilities 3,331,362 3,450,101 528,752 EQUITY Shareholders' equity of Global Cord Blood Corporation 528,752 5,950,000,000 528,752 Ordinary shares - - - - - Ordinary shares issued and outstanding as of March 31 and December 31, 2020, respectively 83 83		7,219,033	/,/13,300	1,102,404
Current liabilities Accounts payable 19,992 9,743 1,493 Accrued expenses and other payables 113,989 128,233 19,653 Operating lease liabilities 1,1/17 3,116 478 Deferred revenue 402,751 423,350 664,881 Income tax payable 32,329 27,038 4,144 Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 18,140 16,990 2,604 Total liabilities 3,331,362 3,450,101 528,752 EQUITY Shareholders' equity of Global Cord Blood Corporation Stareholders' equity of Global Cord Blood Corporation Stare issued and outstanding as of March 31 and December 31, 2020, respectively 83 83 13 Additional paid-in capital 2,101,582 2,101,582 32,2082 32,2082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815) </td <td></td> <td></td> <td></td> <td></td>				
Accounts payable 19,992 9,743 1,493 Accrued expenses and other payables 113,989 128,233 19,653 Operating lease liabilities 1,717 3,116 478 Deferred revenue 402,751 423,350 64,881 Income tax payable 32,329 27,038 4,144 Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 18,140 16,990 2,642 Deferred tax liabilities 18,140 16,990 2,642 Total liabilities 3,331,362 3,450,101 528,752 Shareholders' equity of Global Corporation 500,000,000 shares authorized, 121,687,974 and 121,551,075 5 5 shares issued and outstanding as of March 31 and December 31, 2020, respectively 83 83 13 Additional paid-in capital 2,101,582 2,101,582 322,082 322,082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815)				
Accrued expenses and other payables 113,989 128,233 19,653 Operating lease liabilities 1,717 3,116 478 Deferred revenue 402,751 423,350 64,881 Income tax payable 32,329 27,038 4,144 Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 1,782 195 30 Other non-current liabilities 450,900 473,990 72,642 Deferred tax liabilities 18,140 16,990 2,604 Total liabilities 3,331,362 3,450,101 528,752 Shareholders' equity of Global Cord Blood Corporation 50 50 50 Ordinary shares 50,000,000 shares authorized, 121,687,974 and 121,551,075 83 83 13 Share issued and outstanding as of March 31 and December 31, 2020, respectively 83 83 13 Additional paid-in capital 2,101,582 2,101,582 32,20,882		10.000	0.540	1 400
Operating lease liabilities 1,717 3,116 478 Deferred revenue 402,751 423,350 64,881 Income tax payable 32,329 27,038 4,144 Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 1,782 195 30 Other non-current liabilities 1,782 195 30 Other non-current liabilities 18,140 16,990 2,604 Total liabilities 3,331,362 3,450,101 528,752 EQUITY Shareholders' equity of Global Cord Blood Corporation 528,752 5 Ordinary shares - - - - US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively 83 83 13 Additional paid-in capital 2,101,828 2,101,582 322,082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815)<		· · · · · · · · · · · · · · · · · · ·	-, -	
Deferred revenue 402,751 423,350 64,881 Income tax payable 32,329 27,038 4,144 Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 450,900 473,990 72,642 Deferred tax liabilities 18,140 16,990 2,604 Total liabilities 3,331,362 3,450,101 528,752 EQUITY - - - - Shareholders' equity of Global Cord Blood Corporation - - - Ordinary shares - - - - - US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 share sissued and outstanding as of March 31 and December 31, 2020, respectively 83 83 13 Additional paid-in capital 2,101,582 2,101,582 322,082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815) (2,815) (431) Accumulated other comprehensi				
Income tax payable 32,329 27,038 4,144 Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 450,900 473,990 72,642 Deferred tax liabilities 18,140 16,990 2,604 Total liabilities 3,331,362 3,450,101 528,752 EQUITY Shareholders' equity of Global Cord Blood Corporation V V Ordinary shares - - - - · US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 share sissued and outstanding as of March 31 and December 31, 2020, respectively 83 83 13 Additional paid-in capital 2,101,582 2,101,582 322,082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815) (2,815) (431) Accumulated other comprehensive losses (94,663) (103,593) (15,876)			•	
Total current liabilities 570,778 591,480 90,649 Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 450,900 473,990 72,642 Deferred tax liabilities 18,140 16,990 2,604 Total liabilities 3,331,362 3,450,101 528,752 EQUITY Shareholders' equity of Global Cord Blood Corporation 528,752 528,752 Ordinary shares - - - 528,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively 83 83 13 Additional paid-in capital 2,101,582 2,101,582 322,082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815) (2,815) (431) Accumulated other comprehensive losses (94,663) (103,593) (15,876)				
Non-current deferred revenue 2,289,762 2,367,446 362,827 Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 450,900 473,990 72,642 Deferred tax liabilities 18,140 16,990 2,604 Total liabilities 3,331,362 3,450,101 528,752 EQUITY Shareholders' equity of Global Cord Blood Corporation 528,752 Ordinary shares - - - US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively 83 83 13 Additional paid-in capital 2,101,582 2,101,582 322,082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815) (2,815) (431) Accumulated other comprehensive losses (94,663) (103,593) (15,876)	1 0			
Non-current operating lease liabilities 1,782 195 30 Other non-current liabilities 450,900 473,990 72,642 Deferred tax liabilities 18,140 16,990 2,604 Total liabilities 3,331,362 3,450,101 528,752 EQUITY Shareholders' equity of Global Cord Blood Corporation Ordinary shares - - - US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 83 83 13 Additional paid-in capital 2,101,582 2,101,582 322,082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815) (2,815) (431) Accumulated other comprehensive losses (94,663) (103,593) (15,876)				
Other non-current liabilities450,900473,99072,642Deferred tax liabilities18,14016,9902,604Total liabilities3,331,3623,450,101528,752EQUITYShareholders' equity of Global Cord Blood CorporationOrdinary shares US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively838313Additional paid-in capital2,101,5822,101,582322,082Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)(2,815)(2,815)(431)Accumulated other comprehensive losses(94,663)(103,593)(15,876)				
Deferred tax liabilities18,14016,9902,604Total liabilities3,331,3623,450,101528,752EQUITYShareholders' equity of Global Cord Blood CorporationOrdinary shares US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively838313Additional paid-in capital2,101,5822,101,582322,082Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)(2,815)(2,815)(431)Accumulated other comprehensive losses(94,663)(103,593)(15,876)				
Total liabilities3,331,3623,450,101528,752EQUITY Shareholders' equity of Global Cord Blood CorporationOrdinary shares• US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively838313Additional paid-in capital2,101,5822,101,582322,082Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)(2,815)(2,815)(431)Accumulated other comprehensive losses(94,663)(103,593)(15,876)				
EQUITYShareholders' equity of Global Cord Blood CorporationOrdinary shares- US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively838313Additional paid-in capital2,101,5822,101,582322,082Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)(2,815)(2,815)(431)Accumulated other comprehensive losses(94,663)(103,593)(15,876)				
Shareholders' equity of Global Cord Blood CorporationOrdinary shares- US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively838313Additional paid-in capital2,101,5822,101,582322,082Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)(2,815)(2,815)(431)Accumulated other comprehensive losses(94,663)(103,593)(15,876)	Total liabilities	3,331,362	3,450,101	528,752
Shareholders' equity of Global Cord Blood CorporationOrdinary shares- US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively838313Additional paid-in capital2,101,5822,101,582322,082Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)(2,815)(2,815)(431)Accumulated other comprehensive losses(94,663)(103,593)(15,876)				
Ordinary shares- US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively838313Additional paid-in capital2,101,5822,101,582322,082Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)(2,815)(2,815)(431)Accumulated other comprehensive losses(94,663)(103,593)(15,876)				
- US\$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively 83 83 13 Additional paid-in capital 2,101,582 2,101,582 322,082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815) (2,815) (431) Accumulated other comprehensive losses (94,663) (103,593) (15,876)				
shares issued and outstanding as of March 31 and December 31, 2020, respectively838313Additional paid-in capital2,101,5822,101,582322,082Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)(2,815)(2,815)(431)Accumulated other comprehensive losses(94,663)(103,593)(15,876)				
Additional paid-in capital 2,101,582 2,101,582 322,082 Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815) (2,815) (431) Accumulated other comprehensive losses (94,663) (103,593) (15,876)	• • • • • • • • • • • • • • • • • • • •	00	0.7	10
Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively) (2,815) (2,815) (431) Accumulated other comprehensive losses (94,663) (103,593) (15,876)				
respectively) (2,815) (2,815) (431) Accumulated other comprehensive losses (94,663) (103,593) (15,876)		2,101,582	2,101,582	322,082
Accumulated other comprehensive losses(94,663)(103,593)(15,876)	· · · · · · · · · · · · · · · · · · ·			(124)
Retained earnings 1,877,940 2,258,453 346,122				
Total equity attributable to Global Cord Blood Corporation3,882,1274,253,710651,910				
Non-controlling interests 6,364 11,755 1,802	-			
Total equity 3,888,491 4,265,465 653,712				
Total liabilities and equity 7,219,853 7,715,566 1,182,464	Total habilities and equity	7,219,853	7,715,566	1,182,464

GLOBAL CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Nine Months Ended December 31, 2019 and 2020

-	Three months ended December 31,		Nine months ended December 31,			
-	2019 RMB	2020 RMB	US\$	2019 RMB	2020 RMB	US\$
		(in thousands except p	er share data)		•
Revenues	334,733	290,798	44,567	921,572	857,318	131,389
Cost of revenues	(51,606)	(44,878)	(6,878)	(145,670)	(133,039)	(20,389)
Gross profit	283,127	245,920	37,689	775,902	724,279	111,000
Operating expenses						
Research and development	(6,404)	(8,985)	(1,377)	(17,504)	(18,283)	(2,802)
Sales and marketing	(75,936)	(68,994)	(10,574)	(201,453)	(178,178)	(27,307)
General and administrative	(47,914)	(43,984)	(6,741)	(147,251)	(131,191)	(20,106)
Total operating expenses	(130,254)	(121,963)	(18,692)	(366,208)	(327,652)	(50,215)
Operating income	152,873	123,957	18,997	409,694	396,627	60,785
Other income, net	· · · ·	· · · · ·				· · · · · · · · · · · · · · · · · · ·
Interest income	6,350	7,190	1,102	19,072	22,767	3,489
Foreign currency exchange gains/(losses)	26	75	11	(164)	183	28
Change in fair value of equity securities	8,047	6,003	920	10,983	30,107	4,614
Dividend income			_	507	1,281	196
Others	4,515	2,152	330	5,277	5,070	777
Total other income, net	18,938	15,420	2,363	35,675	59,408	9,104
Income before income tax	171,811	139,377	21,360	445,369	456,035	69,889
Income tax expense	(25,644)	(21,220)	(3,252)	(67,207)	(70,131)	(10,748)
Net income	146,167	118,157	18,108	378,162	385,904	59,141
Net income attributable to non-	140,107	110,107	10,100	576,102	565,504	55,141
controlling interests	(1,154)	(1,587)	(243)	(4,452)	(5,391)	(826)
Net income attributable to Global Cord	(1,104)	(1,007)	(243)	(4,452)	(5,551)	(020)
Blood Corporation's shareholders	145,013	116,570	17,865	373,710	380,513	58,315
blood corporation s shareholders	110,010	110,070	17,000	575,710	500,515	50,515
Earnings per share:						
Attributable to ordinary shares						
- Basic	1.19	0.96	0.15	3.07	3.13	0.48
- Diluted	1.19	0.96	0.15	3.07	3.13	0.48
Other comprehensive losses, net of nil						
income taxes						
 Foreign currency translation 						
adjustments	(30,953)	(4,289)	(657)	(7,800)	(8,930)	(1,369)
Comprehensive income	115,214	113,868	17,451	370,362	376,974	57,772
Comprehensive income attributable to						
non-controlling interests	(1,154)	(1,587)	(243)	(4,452)	(5,391)	(826)
Comprehensive income attributable to	<u> </u>		<u> </u>			
Global Cord Blood Corporation's						
shareholders	114,060	112,281	17,208	365,910	371,583	56,946

GLOBAL CORD BLOOD CORPORATION RECONCILIATION OF NON-GAAP OPERATING INCOME For the Three Months and Nine Months Ended December 31, 2019 and 2020

		Three months ended December 31,			Nine months ended December 31,	
	2019	2019 2020			202	0
	RMB	RMB	US\$	RMB	RMB	US\$
			(in thous	ands)		
GAAP amount of operating income	152,873	123,957	18,997	409,694	396,627	60,785
Depreciation and amortization expenses ⁴	12,140	12,297	1,885	37,040	36,919	5,658
Non-GAAP operating income	165,013	136,254	20,882	446,734	433,546	66,443

⁴ Depreciation and amortization expenses relate to property, plant and equipment and intangible assets respectively.